Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DCC 3084

Next Previous
Drug Profile

DCC 3084

Alternative Names: DCC-3084

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein B-raf inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 13 Feb 2026 Deciphera Pharmaceuticals terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany, Spain, France and USA (PO) (NCT06287463) (CTIS2024-517829-12-00)
  • 13 Feb 2026 Deciphera Pharmaceuticals terminates a phase I/II trial in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Spain, Germany and USA (PO) (NCT06287463) (CTIS2024-517829-12-00)
  • 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top